Search | Clinical Trials Finder

Conditions: Community-acquired Bacterial Pneumonia
Interventions: Solithromycin, Standard of Care; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 2 Months to 17 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 21
States / cities: Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 18 more

Conditions: Staphylococcus Aureus Pneumonia
Interventions: MEDI4893, Placebo; Drug · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia • Detroit, Michigan

Conditions: Pseudomonas Aeruginosa Pneumonia
Interventions: AR-105, Placebo; Drug
Lead sponsor: Aridis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 14
States / cities: Sacramento, California • San Diego, California • Jacksonville, Florida + 9 more

Conditions: Pneumocystis Carinii Pneumonia
Interventions: Antibiotics only, Antibiotics + Corticosteroids, Corticosteroids + antibiotics; Drug
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Primaquine, Clindamycin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Chicago, Illinois + 3 more

Conditions: Community Acquired Bacterial Pneumonia, Paraneumonic Effusion
Interventions: Video Assisted Thorascopic Surgery Thoracostomy Tube Placement & Drainage; Procedure
Lead sponsor: Corewell Health West; Other
Eligibility: 0 Years to 18 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Autoimmune Encephalitis, Celiac Disease, Celiac Disease in Children, Chronic Lyme Disease, Post-treatment Lyme Disease Syndrome, Crohn's Disease, Dysautonomia, Anorexia Nervosa, Bulimia Nervosa, ARFID, Avoidant / Restrictive Food Intake Disorder, Ehlers Danlos Syndrome, Endometriosis, Fibromyalgia (FM), Long COVID, Lupus, Migraines, Mast Cell Activation Syndrome, Multiple Sclerosis, Myalgic Encephalomyelitis (ME), Myasthenia Gravis, Generalized, Myasthenia Gravis in Children, Narcolepsy, Obsessive Compulsive Disorder (OCD), PANDAS, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), POTS - Postural Orthostatic Tachycardia Syndrome, General Anxiety Disorder, Social Anxiety Disorder, PTSD - Post Traumatic Stress Disorder, Psoriasis, Traumatic Brain Injury, Tourette's Syndrome, Inflammatory Bowel Disease (IBD), Autoimmune Diseases, Neurological Diseases or Conditions, Psychiatric Disorder, Sjogren's Syndrome, Ulcerative Colitis and Crohn's Disease
Interventions: Not listed
Lead sponsor: Brain Inflammation Collaborative; Other
Eligibility: 2 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Delafield, Wisconsin

Conditions: Pneumococcal Infections, Pneumonia, Pneumococcal
Interventions: V114, Prevnar 13™; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years and older
Enrollment: 2,340 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 30
States / cities: Chandler, Arizona • Mesa, Arizona • Fountain Valley, California + 26 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Atovaquone, Pentamidine isethionate; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Enrollment: 615 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Maitland, Florida • Tampa, Florida • New York, New York + 2 more

Conditions: Cystic Fibrosis, Pneumonia, Pseudomonas Aeruginosa Infection
Interventions: meropenem; Drug
Lead sponsor: Joseph Kuti; Other
Eligibility: 6 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: Hartford, Connecticut • Indianapolis, Indiana • New York, New York + 4 more

Conditions: Cryptococcal Infection, Cryptococcal Pneumonia, Pulmonary Cryptococcosis, Cryptococcal Meningitis, Cryptococcosis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1993
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Community Acquired Pneumonia
Interventions: lefamulin, Moxifloxacin, Linezolid; Drug
Lead sponsor: Nabriva Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 7
States / cities: Hazard, Kentucky • Shreveport, Louisiana • Minneapolis, Minnesota + 4 more

Conditions: Sinusitis, Bronchitis, Chronic, Pneumonia, Bacterial
Interventions: all macrolide antibiotics, all beta-lactam antibiotics; Drug
Lead sponsor: CPL Associates; Other
Eligibility: Up to 95 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Interventions: Non-interventional; Other
Lead sponsor: Innoviva Specialty Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 12
States / cities: Sacramento, California • Gainesville, Florida • Tampa, Florida + 9 more

Conditions: Ventilator Acquired Pneumonia
Interventions: Acceler8 Pheno; Diagnostic Test
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Colon Cancer, Lung Cancer, Tobacco Use Cessation, Obesity, Pneumonia, Bacterial, Shingles, Hepatitis C
Interventions: Epic Healthy Planet Population Health Module; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 50 Years to 80 Years
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Coccidioidomycosis, Pneumonia
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 14 Years to 99 Years
Enrollment: 651 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 6
States / cities: Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 2 more

Conditions: Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Daniel Benjamin; Other
Eligibility: Up to 21 Years
Enrollment: 3,520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 43
States / cities: Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more

Conditions: Pneumonia, Bacterial
Interventions: Amikacin Inhalation Solution (BAY41-6551), Aerosolized Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 725 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 32
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 27 more

Conditions: Pneumonia, Pneumococcal, Vaccine
Interventions: Pneumococcal Vaccine Education; Behavioral
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years to 64 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Wilkes-Barre, Pennsylvania

Conditions: Pneumonia, Hematologic Malignancy, Pseudomonas Aeruginosa Infection, Bacteremia, Hematopoietic Stem Cell Transplant (HSCT)
Interventions: Ceftolozane / Tazobactam Injection; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Bacterial Pneumonia
Interventions: IV meropenem, I.V. Meropenem, Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h, Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage., tobramycin nebulization; Drug · Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 8
States / cities: San Mateo, California • Gainesville, Florida • Atlanta, Georgia + 5 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Sulfamethoxazole-Trimethoprim; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 40
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 26 more

Search by objective public record fields.

Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia

Study of the Efficacy and Safety of MEDI4893

Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia

Corticosteroids Therapy and Pneumocystis Jirovecii Pneumonia (PCP)

The Safety and Efficacy of Clindamycin and Primaquine in the Treatment of Mild - Moderate Pneumocystis Carinii Pneumonia in Patients With AIDS

Study of Fluid Collection of the Chest in Children With Pneumonia

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)

A Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMX

Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children

Fungal Infection Susceptibility

Aerosols in the Treatment of Pneumocystis Pneumonia: A Pilot Study Quantitating the Deposition of Aerosolized Pentamidine as Delivered in ACTG 040 and Comparing Its Toxicity With Parenteral Pentamidine Therapy

Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia

Outcomes of Patients Not Responding to Antibiotics in the Community

A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection

Study to Determine Quicker Methods of Diagnosing Pneumonia Caused by a Breathing Machine in Critically Ill Patients

Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer

An Observational Study to Assess the Prevalence and Outcomes of Primary Pulmonary Coccidioidomycosis in Persons Aged > / = 14 Years Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (SAnds-PPC)

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia

Pneumonia Vaccine Education Intervention Study

Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation

Clinical Trials to Reduce the Risk of Antimicrobial Resistance

Gradual Initiation of Sulfamethoxazole/Trimethoprim as Primary Pneumocystis Carinii Pneumonia Prophylaxis